ICOS anticorps (PE-Cy5)

N° du produit ABIN2658951

Détail du produit anti-ICOS anticorps (PE-Cy5)

Antigène: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Reactivité: Souris

Hôte: Hamster

Clonalité: Monoclonal

Conjugué: Cet anticorp ICOS est conjugé à/à la PE-Cy5

Application: Cytometry by Time of Flight (CyTOF), ELISA (Capture)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE/Cy5 under optimal conditions. The solution is free of unconjugated PE/Cy5 and unconjugated antibody.

Clone: 15F9

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur ICOS

Antigène: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Autre désignation: CD278 (ICOS Produits)

Synonymes: anticorps ICOS, anticorps AILIM, anticorps CCLP, anticorps CRP-1, anticorps H4, anticorps Ly115, anticorps CD278, anticorps CVID1, anticorps Ailim, anticorps inducible T-cell costimulator, anticorps inducible T cell co-stimulator, anticorps inducible T-cell co-stimulator, anticorps ICOS, anticorps LOC100232284, anticorps Icos

Sujet: CD278 is a 47-57 kD protein, also known as inducible costimulatory molecule (ICOS), or H4. This protein is homologous to the CD28/CTLA-4 proteins. It forms homodimers and is expressed on activated T cells and a subset of thymocytes. It is able to costimulate T cells proliferation. In addition, ICOS has been shown to be involved in humoral immune responses (B cell germinal center formation). The ICOS ligand is B7-H2. ICOS stimulation has been shown to potentiate TCR-mediated IL-4 and IL-10 production and has been proposed to play a role in Th2 cell development. It has also been shown to be involved in airway tolerance and the downregulation of pulmonary inflammation.

Pathways: Cancer Immune Checkpoints